NAPWHA’s Charlie Tredway was asked by Prevention Access Campaign to set an early morning alarm to join their panel at AIDSwatch 2020, focusing on the impact of U=U on Australia, Denton Callender’s presentation at CROI and what works about our HIV response.
As COVID-19 brings in unprecedented measures on how we interact and live our lives, the sense of disconnect has become a challenge for many of us. Even the language of social distancing and isolation can be triggering when contact, intimacy, and togetherness play such a big part in our lives.
The current COVID-19 crisis has raised concerns about HIV treatment supply in Australia. Despite continued assurances that supply is not, nor is likely to be compromised, rumours to the contrary persist. This speculation has the potential to raise anxiety levels and cause consumer panic. NAPWHA has jointly issued a communication with AFAO and ASHM urging the importance of consistent messaging to the HIV health workforce regarding supply of ARVs, which is vitally important at this time of the COVID-19 crisis.
From 1 April 2020 Truvada for HIV treatment and for pre-exposure prophylaxis (PrEP) will no longer be available through the Pharmaceutical Benefits Scheme (PBS). In addition, from October 2020 Atripla will be delisted. We encourage you to talk to your prescribing doctor further regarding generic equivalent/s of both antiretrovirals (ARVs) that are available.
We know how long coronavirus survives on surfaces. Here’s what it means for handling money, food and more
How long does coronavirus survives on surfaces? How can we reduce risk from surfaces and objects? What are some small actions where we can take precautions? Ian M. Mackay and Katherine Arden of The University of Queensland answer in this article.
NAPWHA is looking for a Resources Project Officer to join our dynamic team working from Newtown, Sydney and deliver two exciting education projects in 2020. Applications must be received by 4.00pm Thursday 9 April 2020 (AEST).